Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.61 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RRM1 | P23921 | 1/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776495 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL1263917 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL25885398 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL11246492 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL11594186 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL25885394 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL10708302 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| SCHEMBL29981433 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| Hydrochloric Acid SCHEMBL23001108 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1FAAHSLC6A5 | |
| Hydrochloric Acid SCHEMBL11638490 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1FAAHSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | UNIV MICHIGAN REGENTS (US) | 2023-07-13 | — | — | US | disclosed |
| US-9173956-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-7645805-B2 | Gelling agents | APPLIED NANOSYSTEMS, B.V. (NL) | 2010-01-12 | — | — | US | disclosed |
| US-20090181037-A1 | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses | CENTOCOR ORTHO BIOTECH, INC. | 2009-07-16 | — | — | US | disclosed |
| EP-1506168-B1 | GELLING AGENTS | APPLIED NANOSYSTEMS BV (NL) | 2008-04-30 | — | — | EP | disclosed |
| US-20050250857-A1 | Gelling agents | NANO FIBER MATRICES B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
| EP-1506168-A2 | GELLING AGENTS | Applied NanoSystems B.V. (NL) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097587-A2 | GELLING AGENTS | APPLIED NANOSYSTEMS B.V. (NL) | 2003-11-27 | — | — | WO | disclosed |
| EP-1364941-A1 | Gelling agents | Applied NanoSystems B.V. (NL) | 2003-11-26 | — | — | EP | disclosed |
| WO-1996028458-A1 | SURFACTANT COMPOSITIONS WITH ANTI-MICROBIAL EFFECT | CASTROL LIMITED (GB) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218765-A1 | SMALL MOLECULE DEGRADERS OF SHP2 PROTEIN | PTPN1, PTPRS, PPM1D | CASP2 4306/4885NAAA 4123/4885EPHX1 2891/4885 |
| US-20090181037-A1 | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses | GLP1R, IAPP, GCG | CASP2 3067/4885NAAA 2076/4885EPHX1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.